Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα(q) and Gα(11) and kill uveal melanoma cells

There is no efficacious standard of care therapy for uveal melanoma. Unlike cutaneous disease, uveal melanoma does not exhibit RAS mutations but instead contains mutations with ~90% penetrance in either Gα(q) or Gα(11). Previously we demonstrated that neratinib caused ERBB1/2/4 and RAS internalizati...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Biol Ther
Asıl Yazarlar: Booth, Laurence, Roberts, Jane L., Sander, Cindy, Lalani, Alshad S., Kirkwood, John M., Hancock, John F., Poklepovic, Andrew, Dent, Paul
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2018
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606002/
https://ncbi.nlm.nih.gov/pubmed/30571927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1551747
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller